SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Harris ST 2001 Bisphosphonates for the treatment of postmenopausal osteoporosis: Clinical studies of etidronate and alendronate. Osteoporos Int 12(Suppl 3):S11S16.
  • 2
    Delmas PD 2002 Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 30:1417.
  • 3
    Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359:20182026.
  • 4
    Delmas PD, Meunier PJ 1997 The management of Paget's disease of bone. N Engl J Med 336:558566.
  • 5
    Roux C, Dougados M 1999 Treatment of patients with Paget's disease of bone. Drugs 58:823830.
  • 6
    Coleman RE 2001 Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165176.
  • 7
    Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:20952105.
  • 8
    van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108111.
  • 9
    Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G 2000 Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231241.
  • 10
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235242.
  • 11
    Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581589.
  • 12
    Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ 1999 Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56:131140.
  • 13
    Coxon FP, Helfrich MH, van't Hof RJ, Sebti SM, Ralston SH, Hamilton AD, Rogers MJ 2000 Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:14671476.
  • 14
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653661.
  • 15
    Bijvoet OLM, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paassen HC, Reitsma PH, Te Velde J, de Vries E, van der Wey JP 1980 APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 23:11931204.
  • 16
    Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tiss Int 41:326331.
  • 17
    Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956962.
  • 18
    Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D 1996 Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133139.
  • 19
    Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra DP 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386392.
  • 20
    Kunzmann V, Bauer E, Wilhelm M 1999 Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737738.
  • 21
    Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M 2000 Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384392.
  • 22
    Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR 1995 Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375:155158.
  • 23
    Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt SA, Horton MA, Seabra MC, Ebetino FH, Rogers MJ 2001 Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276:4821348222.
  • 24
    Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagne F, Brailly H, Bonneville M, Fournie JJ 2001 Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem 276:1833718344.
  • 25
    Thompson K, Dunford JE, Ebetino FH, Rogers MJ 2002 Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 290:869873.
  • 26
    Burk MR, Mori L, De Libero G 1995 Human V gamma 9-V delta 2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. Eur J Immunol 25:20522058.
  • 27
    Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U 2001 Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687692.
  • 28
    Das H, Wang L, Kamath A, Bukowski JF 2001 Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98:16161618.
  • 29
    Bukowski JF, Morita CT, Brenner MB 1999 Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: Implications for innate immunity. Immunity 11:5765.
  • 30
    Keller RK, Fliesler SJ 1999 Mechanism of aminobisphosphonate action: Characterization of alendronate inhibition of the isoprenoid pathway. Biochem Biophys Res Commun 266:560563.
  • 31
    Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G 2003 Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197:163168.
  • 32
    Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A 2002 Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:12281236.
  • 33
    Dooley M, Balfour JA 1999 Ibandronate. Drugs 57:101108.
  • 34
    Fitton A, McTavish D 1991 Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289318.
  • 35
    Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P 1992 Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 84:788792.
  • 36
    Schilbach K, Geiselhart A, Handgretinger R 2001 Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood 97:29172918.
  • 37
    O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA 1993 Effective treatment of maligant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 67:560563.
  • 38
    Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K 1996 Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 34:5161.
  • 39
    Miyagawa F, Tanaka Y, Yamashita S, Minato N 2001 Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 166:55085514.
  • 40
    Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N 2003 Requirement of species-specific interactions for the activation of human gammadelta T cells by pamidronate. J Immunol 170:36083613.
  • 41
    Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N 2001 Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 167:50925098.
  • 42
    Zlabinger GJ, Stuhlmeier KM, Eher R, Schmaldienst S, Klauser R, Vychytil A, Watschinger B, Traindl O, Kovarik J, Pohanka E 1992 Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment. J Clin Immunol 12:170177.
  • 43
    Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F 1999 New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413428.
  • 44
    Frith JC, Rogers MJ 2003 Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18:204212.
  • 45
    Belmant C, Espinosa E, Halary F, Tang Y, Peyrat MA, Sicard H, Kozikowski A, Buelow R, Poupot R, Bonneville M, Fournie JJ 2000 A chemical basis for selective recognition of nonpeptide antigens by human delta T cells. FASEB J 14:16691670.
  • 46
    Subauste CS, Chung JY, Do D, Koniaris AH, Hunter CA, Montoya JG, Porcelli S, Remington JS 1995 Preferential activation and expansion of human peripheral blood gamma delta T cells in response to Toxoplasma gondii in vitro and their cytokine production and cytotoxic activity against T. gondii-infected cells. J Clin Invest 96:610619.
  • 47
    Malkovska V, Cigel FK, Armstrong N, Storer BE, Hong R 1992 Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency. Cancer Res 52:56105616.
  • 48
    Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS, Voss SD, Morrissey LW, DeMars R, Welch WJ 1990 Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 250:12691273.
  • 49
    Sicard H, Al Saati T, Delsol G, Fournie JJ 2001 Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med 7:711722.
  • 50
    Tsuji M, Mombaerts P, Lefrancois L, Nussenzweig RS, Zavala F, Tonegawa S 1994 Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice. Proc Natl Acad Sci USA 91:345349.
  • 51
    Feurle J, Espinosa E, Eckstein S, Pont F, Kunzmann V, Fournie JJ, Herderich M, Wilhelm M 2002 Escherichia coli produces phosphoantigens activating human gamma delta T cells. J Biol Chem 277:148154.